---
title: 'Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis
  compared to healthy controls: a five-year follow-up study'
date: '2023-04-20'
linkTitle: http://rd.springer.com/10.1007/s11306-023-02010-0
source: Latest Results for Metabolomics
description: ' <h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section
  id-a-sec1"> <h3 class="a-plus-plus">Introduction and objectives</h3> <p class="a-plus-plus">Multiple
  sclerosis (MS) is a disease of the central nervous system associated with immune
  dysfunction, demyelination, and neurodegeneration. The disease has heterogeneous
  clinical phenotypes such as relapsing–remitting MS (RRMS) and progressive multiple
  sclerosis (PMS), each with unique pathogenesis. Metabolomics research has shown
  promise in understanding the etiologies of MS disease. However, there is a paucity
  of ...'
---
 <h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section id-a-sec1"> <h3 class="a-plus-plus">Introduction and objectives</h3> <p class="a-plus-plus">Multiple sclerosis (MS) is a disease of the central nervous system associated with immune dysfunction, demyelination, and neurodegeneration. The disease has heterogeneous clinical phenotypes such as relapsing–remitting MS (RRMS) and progressive multiple sclerosis (PMS), each with unique pathogenesis. Metabolomics research has shown promise in understanding the etiologies of MS disease. However, there is a paucity of ...